Search...

ACTINOGEN MEDICAL LIMITED

Actinogen Medical Limited Stocks ACW AU000000ACW3 Biotechnology & Medical Research

Market Closed - Australian S.E. 12:10:03 2026-11-19 am EST 1st Jan Change

0.008000 AUD -82.22% -86.89%

Summary Quotes Charts News Company Financials Valuation Consensus Ratings Calen

All News Broker Recommendations Highlights Insiders Transcripts Press Releases Official Publications Other la

Actinogen Medical Limited Announces Topline Results From XanaMIA Phase 2b/3 Trial Of Oral Emestedastat

Published on 11/19/2026 at 09:06 am EST
S&P Capital IQ

Add MarketScreener to your sources Share

ACTINOGEN MEDICAL LIMITED -82.22%

Actinogen Medical Limited announced topline results from its pivotal, placebo-controlled XanaMIA phase 2b/3 trial of oral emestedastat (Xanamem) over 36 weeks of treatment in 247 patients with mild to moderate Alzheimer?s disease and elevated levels of the pTau181 blood biomarker. In a prespecified analysis of participants above the median age of 75 years, a statistically and clinically significant benefit on the Clinical Dementia Rating Scale ? Sum of Boxes (CDR-SB) zero progression rate (40% vs.

22%, p=0.02) for Xanamem was observed, together with a clinically significant rate of 30% disease slowing (mean CDR-SB superiority of 0.39 points at Week 36, p=0.22). These findings may be related to the known increase in the target 11ß-HSD1 enzyme expression with age. This rate of disease slowing is similar to that claimed by Eli Lilly and Eisai for their approved therapies donanemab and lecanemab.

Small and non-significant trends favoring Xanamem on the key secondary endpoints of cognition and ? Activities of Daily Living? were also observed.

The previously established, favorable safety profile for Xanamem 10 mg administered daily for up to 12 weeks was replicated over the longer treatment period of 36 weeks with no serious adverse events attributed to the drug. Xanamem?s novel mechanism of action is to control the level of cortisol in brain, liver and adipose tissue (fat) through the inhibition of the tissue cortisol synthesis enzyme, 11ß-HSD1, without blocking normal production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of tissue cortisol control in regions where 11ß-HSD1 is highly expressed such as the hippocampus and grey matter in the brain, as well as in liver and adipose tissue.

Chronically elevated cortisol is associated with progression in Alzheimer?s Disease and excess cortisol is known to be toxic to brain cells. Elevated cortisol is also associated with more severe forms of depression. Xanamem has demonstrated excellent target enzyme engagement and in human trials has shown potential benefit in older people with Alzheimer?s disease and anti-depressive benefits in patients with moderately severe depression.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

© S&P Capital IQ - 2026

Add MarketScreener to your sources Share



8h	Actinogen Medical Limited Announces Topline Results From XanaMIA Phase 2b/3 Trial Of Oral Emestedastat
Oct. 28	Actinogen Medical Targets Mid-November for Alzheimer's Trial Results Release
Oct. 28	Actinogen Medical Limited Achieves Database Lock In Pivotal XanaMIA Trial Of Oral Xanamem In Alzheimer?s Disease And Narrows Guidance For Final Topline Trial Results To Mid-November
Sep. 23	Actinogen Medical Limited Completes Final Participant Visit for Xanamia Phase 2B/3 Alzheimer?S Disease Clinical Trial
Sep. 22	Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5%
Aug. 31	Actinogen Medical Limited - Special Call
Aug. 27	Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2026
Aug. 05	Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment
Jul. 20	Actinogen Medical Announces Results from Xanamem Phase 2 Depression Proof-Of-Concept Trial
Jul. 19	Actinogen Says Results from Phase Two Trial of Therapy Candidate in Patients with Major Depressive Disorder, Cognitive Impairment Published
Jun. 17	Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10%
May. 28	Actinogen Medical Limited Announces Positive EMA Scientific Advice and Provides Update on Xanamem Alzheimer?s Disease Program
May. 27	Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program
Apr. 01	Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3%

Chart Actinogen Medical Limited

Duration Auto. Period Day



ACW: Dynamic Chart

Company Profile

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimerâ€™s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamemâ€™s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HS…

Employees	6
Sector	Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell Buy

Average target price	**0.0400 AUD**
Spread / Average Target	**+400.00%**

Consensus

Stock Market » Stock Market News »
Actinogen Medical Limited Announces Topline Results From XanaMIA Phase 2b/3 Trial Of Oral Emestedastat

Download on the App Store

OUR EXPERTS ARE HERE FOR YOU
+1 (951) 669-7394

Contact us

Legal information Cookie settings MarketScreener Blog About us
Copyright © 2026 Surperformance SAS. All rights reserved.

Stock quotes are provided by Factset, Morningstar and S&P Capital IQ - Release f789a904